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Objectives: This study was conducted to compare health and cost outcomes utiliz-
ing either Ticagrelor versus Plavix in the management of acute coronary syndrome 
(ACS) patients, and impact of generic Clopidogrel used in Hong Kong. MethOds: A 
decision analytic model was used to perform a cost-effectiveness analysis of treat-
ing ACS patients for one year with Ticagrelor plus aspirin strategy compared with 
Plavix (or generic Clopidogrel) plus aspirin strategy from Hong Kong health care pro-
vider perspective. To estimate discounted (3%) lifetime costs, quality-adjusted life 
years (QALYs), and incremental cost-effectiveness ratios (ICERs). The health states 
in the model included patient in ACS without event, myocardial infarction (MI), and 
death from vascular cause. The model simulates a cohort of 45-year-old patients 
with ACS, and Markov cycle is one year. The time horizon was lifetime (85 years old). 
Event rates were adopted from the PLATO study, and the ACS registry in the Prince of 
Wales Hospital (PWH) in Hong Kong. Probabilistic sensitivity analyses using Monte 
Carlo simulations were conducted to assess parameter uncertainty. Results: 
Compared with the Plavix (or generic Clopidogrel) treatment strategy, the Ticagrelor 
treatment strategy for ACS, STEMI, and UA / NSTEMI patients were associated with 
ICERs of HK$ 34,441(35,304), HK$ 32,753(33,567), HK$ 39,343(40,417) (1US$ = 7.8HK$) 
per QALY gained, respectively. Ticagrelor treatment strategy was cost-effective over 
99% of the Monte Carlo simulation using a cost-effectiveness threshold of < 1x GDP 
per capita of Hong Kong. cOnclusiOns: The Ticagrelor strategy is considered cost-
effective at three times per capita GDP threshold compared with Plavix or generic 
Clopidogrel strategy in the management of ACS patients in Hong Kong. The impact 
of ICER values of generic clopidogrel compared with Plavix is not significant even 
the sextuple cost in Hong Kong.
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Objectives: Catheter ablation, an expensive procedure with high Atrial Fibrillation 
(AF) recurrence rate, is indicated in patients refractory to drug therapy or in patients 
with drug tolerability issues. The study examines the CE of MRI-guided ablation 
vs. current standard of care (SoC) of ablating all eligible patients in preventing 
AF. MethOds: A decision tree model was developed with a payer perspective 
over a 1-year time horizon. Participants of the DECAAF trial (n= 260), prospective 
multicenter-blinded study, were categorized to Utah Stage I (19%), II (41%), III (31%), 
and Stage IV (9%) based on degree of atrial structural remodeling quantified using 
delayed enhancement MRI. Proportion of patients with post ablation AF recurrence 
for Utah Stage I-IV was 16.33%, 30.84%, 45.68%, and 58.33% respectively. Survival 
from outcomes was considered as effectiveness. Selective ablation was defined as 
ablating Stage I and II AF patients and medically managing Stage III and IV patients. 
Recurrence rates from the DECAAF trial and other costs and probabilities from the 
literature were used in the model. Probabilistic sensitivity analysis was conducted 
on all variables in the model. Results: The mean total per patient annual cost in 
the MRI-guided selective ablation cohort was $23,238 compared to $28,659 for the 
SoC ablates all cohorts. However, no significant – clinical or statistical, difference 
in effectiveness was observed. The higher cost of the ablate all cohort was associ-
ated with higher AF recurrence and costs of AF treatment. Probabilistic sensitivity 
analysis demonstrated the similar substantial difference between two procedures. 
The probability associated with AF recurrence in SoC was most sensitive varia-
ble. cOnclusiOns: MRI-guided selective ablation is economically beneficial with 
annual savings of $5,421 per person with same effectiveness compared to current 
SoC. Future research taking QoL and age into account is warranted to help payers 
assess the CE of ablation procedure in AF patients.
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Objectives: Value-based insurance design (VBID) programs aim to encourage 
patient use of high value health care services, often with the goal of reducing 
overall cost. We investigate a hypothetical VBID program of copay elimination 
for statins to determine if it is cost saving and cost effective. MethOds: The 
Archimedes Model was used to simulate the outcomes of increased statin adher-
ence due to copay elimination. 10,000 individuals representative of US population 
who had been prescribed statins were modeled over a 10 year timeframe, sub-
jected to a two-arm virtual trial: one arm represents current care and the other 
arm represents copay elimination. Based on a literature review, statin adherence 
rates were increased by 3% in the copay elimination arm. Statin prices, based 
on generic prices, were $12/mo for Atorastatin80, $4/mo for Simvastatin80, and 
$3/mo for all other Simvastatin doses. Results: The VBID program failed to be 
cost saving, costing insurers $20 per person per year over the 10 year timeframe. 
The program saved 37 life years and 33 QALYs at a discounted cost of $66,000 per 
discounted QALY with 0.03 discount rate. For shorter timeframes the average 
cost remained constant and the program was even less cost effective. Follow-up 
simulations and analyses show that the program is increasingly cost effective in 
high risk subpopulations. For a population(n= 928) ages 60 to 70 with diabetes and 
prior MIs the program became cost saving after 12 years, having saved $94,000 
over 20 years. cOnclusiOns: The proposed VBID program failed to be cost sav-
ing because the benefit of increased statin adherence was small compared to the 
cost of copay elimination for all statin users. This failure to find cost savings is 
consistent with the published observational studies. To achieve cost savings VBID 
programs should be targeted according to individual risk.
PCV82
COSt-effeCtIVeneSS Of rIVarOxaban VerSuS dabIGatran fOr 
thrOmObOPrOPhylaxIS In tOtal hIP rePlaCement SurGery In the 
unIted StateS
Raval A.1, Vyas A.1, Kamal K.2
1West Virginia University, Morgantown, WV, USA, 2Duquesne University Mylan School of 
Pharmacy, Pittsburgh, WV, USA
Objectives: American College of Chest Physicians (ACCP) guideline recommends 
the use oral medication either rivaroxaban or dabigtran in patients who are under-
going major orthopedic surgery and decline injections. This study assessed the 
cost-effectiveness of rivaroxaban verus dabigatran for prevention of venous throm-
boembolism (VTE) and bleeding episode after total hip replacement (THR) surgery 
from Medicare perspective. MethOds: A 6-month decision-tree model was devel-
oped to compare the cost-effectiveness of rivaroxaban and dabigatran for THR. 
Treatment efficacy and safety data such as probabilities of distal and proximal deep 
vein thrombosis (DVT), symptomatic pulmonary embolism (PE), and major bleeding 
were derived from randomized controlled trials and systematic reviews. Cost of 
medications were derived from the Redbook (2012) and cost of DVT, PE and major/
minor bleeding episodes were based on diagnosis code related payment (2009). 
Guidelines consistent diagnosis procedure for VTE and current procedure terminol-
ogy (CPT) codes were utilized for determining procedure costs. All cost data was 
adjusted to 2012 dollars. A discount rate of 3% was applied to base-case analysis 
and sensitivity analysis were conducted to characterize uncertainty in the decision 
model. Results: The prophylaxis medication cost for rivoraxaban and dabigatran 
was $422.51 and $392.61, respectively for per person per event. The cost of treating 
major bleeding episode and VTE were $14,548.09 and $14,114.80, respectively per 
person per event. There were absence of any head-to-head studies comparing the 
dabigatran and rivaroxaban. Compared to standards heparin regimen, rates of bleed-
ing events did not differ significantly between dabigatran etexilate and rivaroxaban. 
However, the rates of having VTE event were higher in rivaroxaban compared to The 
prophylaxis treatment with dabigatran was $164.40 less costly than rivaroxaban for 
prevention of VTE and bleeding episode in patient undergoing THR. cOnclusiOns: 
Dabigatran and rivaroxaban share similar adverse events profiles, however, dabi-
gatran was found to be more cost-saving compared to rivaroxaban.
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Objectives: To evaluate the cost-effectiveness of diagnosis with an ILR following 
Standard Testing (ST) after a syncopal event from a United States payer perspec-
tive. MethOds: This analysis considers all costs of diagnosis via ST and ILR, the 
costs and consequences of recurrent syncope, and the cost of arrhythmia treat-
ment following diagnosis. A Markov model was developed to reflect the recurrence 
of syncopal events in undiagnosed patients. Due to documented differences in 
the prevalence of arrhythmia between patients with suspected arrhythmia and 
patients with unexplained syncope we considered the two populations separately, 
each over a 10-year time horizon. All costs and consequences were discounted at 
a 3% annual rate. Results: The results are similar for suspected arrhythmia and 
unexplained syncope. In the suspected arrhythmia population, the incremental cost 
of the ILR strategy is $14,712. The incremental Quality Adjusted Life Years (QALY) are 
estimated to be between 0.2806 and 0.4282, and the incremental cost-effectiveness 
ratio (ICER) is between $34,400 and $52,400. The syncopal events avoided with ILR 
are 402 per 1,000 patients. In the unexplained syncope population the incremental 
costs and effects are lower compared to the previous case: $13,800, and between 
0.2174 and 0.3317 QALYs gained. The ICER is between $41,600 and $63,500 per QALY 
gained. The number of syncopal events avoided with ILR is 311 per 1,000 patients. 
In 1,000 patients the ILR strategy is estimated to identify between 300 and 380 more 
arrhythmia cases compared to ST in the two populations. cOnclusiOns: When 
considering all costs in combination with the syncopal events avoided and quality 
of life (QoL), ILR arrhythmia diagnosis is a cost-effective alternative to ST. The use 
of ILR increases the diagnostic yield in both populations and guides treatment in 
more patients compared to ST.
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Objectives: The main goal of treatments for AF is stroke prevention since the 
annual risk of stroke is 5–6 times greater in patients with AF than in people with 
a normal heart rhythm. [1] The incidence of AF increases from less than 0.1% per 
year in those under 40 years old to exceed 1.5% per year in women and 2% in 
men older than 80. [2] This study assesses the cost-effectiveness (CE) of Apixaban 
versus other anticoagulation therapies for prevention on NVAF, from the private 
health care perspective. MethOds: A Markov decision-tree model was made to 
compare costs and effectiveness of Warfarin (5 mg/24 hours), Apixaban (5 mg/12 
hours), Dabigatran (110 mg/12 hours and 150 mg/12 hours), and Rivaroxaban (20 
mg/24 hours) in a simulated cohort of 1000 patients with AF. Effectiveness meas-
ures were: stroke, bleeding, myocardial infarction (MI) rates and deaths. Local costs 
were gathered from Trinidad’s Private Health System databases (US$, 2013) and only 
